Beta3_LVH: towards a treatment against heart failure

  • Contact

  • Home

  • Our Partners

  • The clinical trial

  • A bit of science...

  • News

  • More

    Mirabegron

    Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

     

    It is commercialised in Europe by Astellas pharma as Betmiga.

    Back to science »

    © 2015 created with Wix.com

    Follow us

    More

    Public disclosures
    Q&A

    This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 634559

    For partners only
    Share